- Home
- OPFI vs NGNE Comparison
OPFI vs NGNE Comparison
Compare OPFI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- NGNE
- Stock Information
- Founded
- OPFI 2009
- NGNE 2003
- Country
- OPFI United States
- NGNE United States
- Employees
- OPFI N/A
- NGNE N/A
- Industry
- OPFI Finance: Consumer Services
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- NGNE Health Care
- Exchange
- OPFI Nasdaq
- NGNE Nasdaq
- Market Cap
- OPFI 300.3M
- NGNE 325.3M
- IPO Year
- OPFI N/A
- NGNE N/A
- Fundamental
- Price
- OPFI $10.46
- NGNE $19.95
- Analyst Decision
- OPFI Buy
- NGNE Strong Buy
- Analyst Count
- OPFI 2
- NGNE 7
- Target Price
- OPFI $11.75
- NGNE $41.86
- AVG Volume (30 Days)
- OPFI 1.1M
- NGNE 113.3K
- Earning Date
- OPFI 11-06-2025
- NGNE 08-11-2025
- Dividend Yield
- OPFI 9.56%
- NGNE N/A
- EPS Growth
- OPFI N/A
- NGNE N/A
- EPS
- OPFI N/A
- NGNE N/A
- Revenue
- OPFI $320,831,000.00
- NGNE N/A
- Revenue This Year
- OPFI $116.69
- NGNE N/A
- Revenue Next Year
- OPFI $9.90
- NGNE N/A
- P/E Ratio
- OPFI N/A
- NGNE N/A
- Revenue Growth
- OPFI 31.26
- NGNE N/A
- 52 Week Low
- OPFI $3.93
- NGNE $6.88
- 52 Week High
- OPFI $17.73
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- OPFI 48.70
- NGNE 48.86
- Support Level
- OPFI $9.81
- NGNE $18.00
- Resistance Level
- OPFI $10.29
- NGNE $19.93
- Average True Range (ATR)
- OPFI 0.45
- NGNE 1.03
- MACD
- OPFI 0.11
- NGNE 0.01
- Stochastic Oscillator
- OPFI 79.17
- NGNE 55.71
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.